Breaking News
Get 50% Off 0
🏄 Grow your portfolio even on vacation with InvestingPro | Summer Sale 50% OFF
CLAIM SALE
Close

Mochida Pharmaceutical (4534)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3,165.0 -45.0    -1.40%
07:30:29 - Closed. Currency in JPY
Type:  Equity
Market:  Japan
ISIN:  JP3922800002 
  • Volume: 17,300
  • Bid/Ask: 3,150.0 / 3,185.0
  • Day's Range: 3,160.0 - 3,195.0
Mochida Pharmaceutical 3,165.0 -45.0 -1.40%

Mochida Pharmaceutical Company Profile

 
Get an in-depth profile of Mochida Pharmaceutical, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

1508

Equity Type

ORD

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker; Dinagest, an agent for endometriosis, adenomyosis, and dysmenorrhea; Lexapro, an antidepressant; Tamcet, an analgesic for chronic pain; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Heparin Sodium MOCHIDA anticoagulant agents. The company also develops mesalazine for the treatment of ulcerative colitis; tocilizumab for the treatment of rheumatoid arthritis; dotinurad for the treatment of gout and hyperuricemia; dienogest formulation for dysmenorrhea; treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and icosapent for hypertriglyceridemia. In addition, it develops medical devices, including dMD-001 that is used for the treatment of articular cartilage lesions; dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for post-operative adhesion. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

Contact Information

Address 7, Yotsuya 1-chome Shinjuku-ku
Tokyo, 160-8515
Japan
Phone 81 3 3358 7211
Fax -

Top Executives

Name Age Since Title
Naoyuki Mochida 66 1999 President & Chairperson
Yoshiharu Hashimoto 62 2019 Full-Time Audit & Supervisory Board Member
Kyosuke Wagai 72 2016 Outside Audit & Supervisory Board Member
Shigeaki Yoshikawa 63 2023 Independent Outside Director
Tomoaki Sonoda 64 2022 Independent Outside Director
Yoshifumi Miyata 73 2021 Outside Audit & Supervisory Board Member
Mami Kobayashi 61 2024 Independent Outside Director
Sanae Tanaka 63 2025 Independent Outside Director
Masayoshi Takeda 64 2022 Full-Time Audit & Supervisory Board Member
Akiko Suzuki 76 2019 Outside Audit & Supervisory Board Member
Chu Sakata 66 2011 Director & Advisor
Junichi Sakaki 65 2014 Senior Executive Managing Officer & Representative Director
Yutaka Kawakami 66 2019 Executive Managing Officer Executive Director
Junichi Nezu 59 2023 Executive Managing Officer & Director
Motoi Mitsuishi 62 2023 Senior Executive Managing Officer & Representative Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4534 Comments

Write your thoughts about Mochida Pharmaceutical
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email